- Home
- HGTY vs ABUS Comparison
HGTY vs ABUS Comparison
Compare HGTY & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HGTY
- ABUS
- Stock Information
- Founded
- HGTY 1984
- ABUS 2005
- Country
- HGTY United States
- ABUS United States
- Employees
- HGTY N/A
- ABUS N/A
- Industry
- HGTY Specialty Insurers
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- HGTY Finance
- ABUS Health Care
- Exchange
- HGTY Nasdaq
- ABUS Nasdaq
- Market Cap
- HGTY 1.1B
- ABUS 906.7M
- IPO Year
- HGTY N/A
- ABUS N/A
- Fundamental
- Price
- HGTY $13.64
- ABUS $4.48
- Analyst Decision
- HGTY Hold
- ABUS Strong Buy
- Analyst Count
- HGTY 7
- ABUS 2
- Target Price
- HGTY $13.83
- ABUS $5.00
- AVG Volume (30 Days)
- HGTY 135.8K
- ABUS 950.0K
- Earning Date
- HGTY 11-04-2025
- ABUS 11-13-2025
- Dividend Yield
- HGTY N/A
- ABUS N/A
- EPS Growth
- HGTY 241.11
- ABUS N/A
- EPS
- HGTY 0.36
- ABUS N/A
- Revenue
- HGTY $1,360,017,000.00
- ABUS $14,606,000.00
- Revenue This Year
- HGTY $16.08
- ABUS $138.02
- Revenue Next Year
- HGTY N/A
- ABUS N/A
- P/E Ratio
- HGTY $37.43
- ABUS N/A
- Revenue Growth
- HGTY 17.92
- ABUS 116.64
- 52 Week Low
- HGTY $8.03
- ABUS $2.71
- 52 Week High
- HGTY $13.80
- ABUS $5.10
- Technical
- Relative Strength Index (RSI)
- HGTY 74.14
- ABUS 48.51
- Support Level
- HGTY $10.98
- ABUS $4.41
- Resistance Level
- HGTY $13.80
- ABUS $4.87
- Average True Range (ATR)
- HGTY 0.54
- ABUS 0.24
- MACD
- HGTY 0.30
- ABUS -0.01
- Stochastic Oscillator
- HGTY 96.76
- ABUS 27.27
About HGTY Hagerty Inc.
Hagerty Inc is a provider of specialty automotive insurance. The company underwrites, sells, and services classic car and enthusiast vehicle insurance policies. Substantial revenue is derived from Commission and fees. Geographically it serves Europe, Canada, and the United States.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.